ImageneBio Inc. Common Stock (IMA)

About IMA

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Onco…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

18

Website

inmagenebio.com/

Fundamentals

1-day range

$5.32$5.35

Market cap

$63.61M

P/E (trailing)

—

P/E (forward)

-1.24

EPS (trailing)

$-5.40

Dividend yield

—

Beta

0.73

Avg. volume

12.0K

Forecasts

3 analyst ratings

ImageneBio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IMA

  ImageneBio Inc. Common Stock

  $5.34

  ▲ 0.19%
  Market cap $63.61MP/E —
  $3.94$13.98
• XTNT

  Xtant Medical Holdings Inc. Common Stock

  $0.4055

  ▲ 22.88%
  Market cap $61.72MP/E 23.84
  $0.2702$0.95
• GNTA

  Genenta Science S.p.A. American Depositary Shares

  $1

  ▼ 1.96%
  Market cap $67.99MP/E —
  $0.55$10
• OKYO

  OKYO Pharma Limited Ordinary Shares

  $1.67

  ▲ 7.74%
  Market cap $56.51MP/E —
  $1.34$3.2
• SCLX

  Scilex Holding Company Common Stock

  $5.42

  ▼ 2.69%
  Market cap $55.70MP/E —
  $4.2$34.27
• INKT

  MiNK Therapeutics Inc. Common Stock

  $11.43

  ▼ 2.16%
  Market cap $53.26MP/E —
  $8.48$16.98
• ATRA

  Atara Biotherapeutics Inc. Common Stock

  $9.16

  ▼ 0.97%
  Market cap $77.04MP/E —
  $3.92$19.15

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Initiates Coverage On ImageneBio with Buy Rating, Announces Price Target of $28
  benzinga · 8/21/2026
• HC Wainwright & Co. Initiates Coverage On ImageneBio with Buy Rating, Announces Price Target of $28
  Benzinga · 8/21/2026
• ImageneBio Files Prospectus For Offering $200M Mixed Shelf
  Benzinga · 8/5/2026
• ImageneBio Q2 EPS $(0.63) Beats $(1.05) Estimate
  Benzinga · 8/5/2026

• Kristin Yarema · July 25, 2026 · J

  115.1K
• Kristin Yarema · July 25, 2026 · Option Exercise

  38.4K
• Robert B. Lally · July 17, 2026 · Sale

  1.5K @ $5.34
• Robert B. Lally · July 16, 2026 · Sale

  1.7K @ $5.5
• David P. Bonita · June 16, 2026 · Grant

  15.6K
• Jonathan Jian Wang · June 16, 2026 · Grant

  15.6K
• Otello Stampacchia · June 16, 2026 · Grant

  15.6K
• Joseph P. Slattery · June 16, 2026 · Grant

  15.6K
• David P. Bonita · April 14, 2026 · Buy

  384.7K
• David P. Bonita · April 14, 2026 · Buy

  336.6K
• ORBIMED ADVISORS LLC · April 14, 2026 · Buy

  384.7K
• ORBIMED ADVISORS LLC · April 14, 2026 · Buy

  336.6K
• Kristin Yarema · March 16, 2026 · Grant

  128.1K
• Kristin Yarema · March 16, 2026 · Grant

  85.4K

Institutional Ownership

March 31, 2026

Total shares held

5.33M

Total value held

$26.56M

Institutional holders

35